Luca Toschi

6.1k total citations · 1 hit paper
97 papers, 3.3k citations indexed

About

Luca Toschi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Luca Toschi has authored 97 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Pulmonary and Respiratory Medicine, 66 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Luca Toschi's work include Lung Cancer Treatments and Mutations (59 papers), Cancer Immunotherapy and Biomarkers (23 papers) and Colorectal Cancer Treatments and Studies (22 papers). Luca Toschi is often cited by papers focused on Lung Cancer Treatments and Mutations (59 papers), Cancer Immunotherapy and Biomarkers (23 papers) and Colorectal Cancer Treatments and Studies (22 papers). Luca Toschi collaborates with scholars based in Italy, United States and Switzerland. Luca Toschi's co-authors include Federico Cappuzzo, Giovanna Finocchiaro, Stefania Bartolini, Armando Santoro, Marileila Varella‐Garcia, Elisa Rossi, Pasi A. Jänne, Egesta Lopci, Sabrina Rossi and Massimo Roncalli and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Luca Toschi

88 papers receiving 3.2k citations

Hit Papers

Increased MET Gene Copy Number Negatively Affects Surviva... 2009 2026 2014 2020 2009 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients
    2009 455 citations Federico Cappuzzo, Margaret C. Skokan et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luca Toschi Italy 28 1.9k 1.9k 989 610 459 97 3.3k
Giovanna Finocchiaro Italy 25 1.6k 0.8× 1.6k 0.8× 890 0.9× 451 0.7× 126 0.3× 67 2.7k
Erminia Massarelli United States 32 3.2k 1.7× 2.1k 1.1× 1.2k 1.3× 648 1.1× 370 0.8× 140 4.6k
Andrew Weickhardt Australia 23 2.3k 1.2× 2.3k 1.2× 967 1.0× 527 0.9× 265 0.6× 111 3.4k
Lowell L. Hart United States 37 3.5k 1.8× 2.2k 1.2× 1.7k 1.7× 763 1.3× 296 0.6× 127 5.5k
Kenichi Suda Japan 35 2.5k 1.3× 2.8k 1.4× 1.7k 1.7× 890 1.5× 219 0.5× 130 4.3k
Drew Rasco United States 33 2.4k 1.2× 980 0.5× 1.7k 1.8× 516 0.8× 296 0.6× 192 4.1k
Oleg Gladkov Russia 18 1.8k 0.9× 2.3k 1.2× 1.8k 1.8× 1.1k 1.8× 229 0.5× 65 3.7k
Davey B. Daniel United States 19 2.2k 1.2× 2.1k 1.1× 538 0.5× 688 1.1× 167 0.4× 82 3.3k
Dimitrios Bafaloukos Greece 34 3.0k 1.6× 1.6k 0.8× 1.2k 1.2× 867 1.4× 242 0.5× 132 4.5k
Daniel J. Freeman United States 18 2.8k 1.5× 1.0k 0.5× 1.3k 1.3× 768 1.3× 261 0.6× 40 3.9k

Countries citing papers authored by Luca Toschi

Since Specialization
Citations

This map shows the geographic impact of Luca Toschi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luca Toschi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luca Toschi more than expected).

Fields of papers citing papers by Luca Toschi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luca Toschi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luca Toschi. The network helps show where Luca Toschi may publish in the future.

Co-authorship network of co-authors of Luca Toschi

This figure shows the co-authorship network connecting the top 25 collaborators of Luca Toschi. A scholar is included among the top collaborators of Luca Toschi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luca Toschi. Luca Toschi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kirienko, Margarita, Fabrizia Gelardi, Paola Bossi, et al.. (2024). Challenging the significance of SUV-based parameters in a large-scale retrospective study on lung lesions. Cancer Imaging. 24(1). 162–162. 2 indexed citations
2.
Lococo, Filippo, Alessandra Cancellieri, Marco Chiappetta, et al.. (2023). Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results. Clinical Lung Cancer. 24(5). 467–473. 4 indexed citations
3.
Rossi, Sabrina, Pierina Navarria, Elena Clerici, et al.. (2023). The Era of Immunotherapy in Small-Cell Lung Cancer: More Shadows Than Light?. Cancers. 15(24). 5761–5761. 4 indexed citations
4.
Veronesi, Giulia, Pierluigi Novellis, Elisa Dieci, et al.. (2020). Favorable incremental cost-effectiveness ratio for lung cancer screening in Italy. Lung Cancer. 143. 73–79. 22 indexed citations
5.
Castello, Angelo, et al.. (2020). The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors. Journal of Cancer Research and Clinical Oncology. 146(5). 1235–1243. 35 indexed citations
6.
Castello, Angelo, Sabrina Rossi, Luca Toschi, & Egesta Lopci. (2020). Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1. Frontiers in Oncology. 10. 1090–1090. 13 indexed citations
7.
Castello, Angelo, et al.. (2019). Hyperprogressive Disease in Patients with Non–Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of 18F-FDG PET/CT. Journal of Nuclear Medicine. 61(6). 821–826. 61 indexed citations
8.
Grizzi, Fabio, Angelo Castello, Dorina Qehajaj, et al.. (2019). Independent expression of circulating and tissue levels of PD-L1: correlation of clusters with tumor metabolism and outcome in patients with non-small cell lung cancer. Cancer Immunology Immunotherapy. 68(9). 1537–1545. 10 indexed citations
9.
Castello, Angelo, Luca Toschi, Sabrina Rossi, et al.. (2019). Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy. Clinical Lung Cancer. 21(1). 28–36. 7 indexed citations
10.
Veronesi, Giulia, Simone Ghislandi, Elena Vanni, et al.. (2018). P3.11-25 Analysis Indicates Low Incremental Cost-Effectiveness Ratio for Implementation of Lung Cancer Screening in Italy. Journal of Thoracic Oncology. 13(10). S968–S968.
11.
Pittiglio, Rosanna, Filippo Reganati, & Luca Toschi. (2017). How to detect illegal waste shipments? The case of the international trade in polyethylene waste. Economics bulletin. 37(4). 2625–2640. 5 indexed citations
12.
Rose, Fiorenza De, Luca Cozzi, Pierina Navarria, et al.. (2015). Clinical Outcome of Stereotactic Ablative Body Radiotherapy for Lung Metastatic Lesions in Non-small Cell Lung Cancer Oligometastatic Patients. Clinical Oncology. 28(1). 13–20. 40 indexed citations
13.
Toschi, Luca, Giovanna Finocchiaro, Teresa T. Nguyen, et al.. (2014). Increased SOX2 Gene Copy Number Is Associated with FGFR1 and PIK3CA Gene Gain in Non-Small Cell Lung Cancer and Predicts Improved Survival in Early Stage Disease. PLoS ONE. 9(4). e95303–e95303. 58 indexed citations
14.
Toschi, Luca & Federico Cappuzzo. (2010). Impact of biomarkers on non-small cell lung cancer treatment. Targeted Oncology. 5(1). 5–17. 13 indexed citations
15.
Cappuzzo, Federico, Giovanni Tallini, Giovanna Finocchiaro, et al.. (2009). Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Annals of Oncology. 21(3). 562–567. 67 indexed citations
16.
17.
Finocchiaro, Giovanna, Luca Toschi, I. Garassino, et al.. (2007). EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?. Expert Opinion on Medical Diagnostics. 1(2). 183–191. 2 indexed citations
18.
Cappuzzo, Federico, Luca Toschi, Giovanni Tallini, et al.. (2006). Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Annals of Oncology. 17(7). 1120–1127. 84 indexed citations
19.
Metro, Giulio, Giovanna Finocchiaro, Luca Toschi, et al.. (2006). Epidermal Growth Factor Receptor (EGFR) Targeted Therapies in Non- Small Cell Lung Cancer (NSCLC). Reviews on Recent Clinical Trials. 1(1). 1–13. 45 indexed citations
20.
Cappuzzo, Federico, Stefania Bartolini, Giovanni Luca Ceresoli, et al.. (2004). Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). British Journal of Cancer. 90(1). 82–86. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giovanna Finocchiaro Breakdown of academic impact, for papers by Erminia Massarelli Breakdown of academic impact, for papers by Andrew Weickhardt Breakdown of academic impact, for papers by Lowell L. Hart Breakdown of academic impact, for papers by Kenichi Suda Breakdown of academic impact, for papers by Drew Rasco Breakdown of academic impact, for papers by Oleg Gladkov Breakdown of academic impact, for papers by Davey B. Daniel Breakdown of academic impact, for papers by Dimitrios Bafaloukos Breakdown of academic impact, for papers by Daniel J. Freeman
Rankless by CCL
2026